Cost-effectiveness of caries-preventive fluoride varnish applications in clinic settings among patients of low, moderate and high risk

被引:39
作者
Schwendicke, Falk [1 ]
Splieth, Christian H. [2 ]
Thomson, William Murray [3 ]
Reda, Seif [1 ]
Stolpe, Michael [4 ]
Page, Lyndie Foster [3 ]
机构
[1] Charite, Dept Operat & Prevent Dent, Berlin, Germany
[2] Univ Med Greifswald, Dept Prevent & Pediat Dent, Greifswald, Germany
[3] Univ Otago, Dept Oral Sci, Fac Dent, Otago, New Zealand
[4] Kiel Inst World Econ, Kiel, Germany
关键词
computer modelling; fluoride; public dental health; topical fluorides; varnish; RANDOMIZED CONTROLLED-TRIAL; MEDICAID-ENROLLED CHILDREN; EARLY-CHILDHOOD CARIES; ROOT-CANAL TREATMENT; ORAL-HEALTH; FOLLOW-UP; CARE; RESTORATIONS; INEQUALITY; SURVIVAL;
D O I
10.1111/cdoe.12320
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: The total body of evidence finds fluoride varnish effective to prevent caries. However, most trials were conducted in high-risk populations, with more recent trials on low-risk groups finding a lower efficacy. We aimed to assess the cost-effectiveness of fluoride varnish application in clinic setting in populations with different caries risk. Methods: A mixed public-private-payer perspective in the context of German health care was performed using a lifetime Markov model. Effectiveness data were derived from an update of the most recent systematic Cochrane review and synthesized in three different risk groups according to control group caries increment via random-effects meta-analysis. Varnish was assumed to be applied twice yearly between age 6 and 18 years. Teeth with carious defects would be treated restoratively and could experience further follow-up treatments. Costs were deduced from German fee item catalogues. Monte Carlo microsimulations were used for to analyse lifetime treatment costs and caries increment (Euro/Decayed, Missing, Filled Teeth (DMFT)). Results: In low-risk groups, fluoride varnish was nearly twice as costly and minimally more effective (293 Euro, 8.1 DMFT) than no varnish (163 Euro, 8.5 DMFT). The incremental cost-effectiveness ratio (ICER) was 343 Euro spent per avoided DMFT. The ICER was lower in medium-risk (ICER 93 Euro/DMFT) and high-risk groups (8 Euro/DMFT). Conclusions: Application of fluoride varnish in the clinic setting is unlikely to be cost-effective in low-risk populations. There is the need to either target high-risk groups or to provide fluoride varnish at lower costs, possibly in nonclinic settings.
引用
收藏
页码:8 / 16
页数:9
相关论文
共 42 条
  • [21] Cost-effectiveness of a technology-supported multimodal prehabilitation program in moderate-to-high risk patients undergoing lung cancer resection: randomized controlled trial protocol
    Barberan-Garcia, Anael
    Navarro-Ripoll, Ricard
    Sanchez-Lorente, David
    Moises-Lafuente, Jorge
    Boada, Marc
    Messaggi-Sartor, Monique
    Gonzalez-Vallespi, Laura
    Montane-Muntane, Mar
    Alsina-Restoy, Xavier
    Campero, Betina
    Lopez-Baamonde, Manuel
    Romano-Andrioni, Barbara
    Guzman, Rudith
    Lopez, Antonio
    Arguis, Maria Jose
    Roca, Josep
    Martinez-Palli, Graciela
    BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)
  • [22] Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients
    Hale, Andrew
    Merlo, Greg
    Nissen, Lisa
    Coombes, Ian
    Graves, Nicholas
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [23] Effectiveness of topical 25% silver nitrate solution followed by 5% fluoride varnish compared to 38% silver diamine fluoride in arresting and preventing dental caries among beta-thalassemia major patients: A randomized clinical trial
    Kayasth, Jagreeti
    Yadav, Vipul
    Manjunath, B. C.
    Atri, Sudhir
    Kumar, Adarsh
    Goel, Shubhi
    Sabbarwal, Bhavna
    JOURNAL OF DENTISTRY, 2024, 150
  • [24] Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
    Neilan, Anne M.
    Bulteel, Alexander J. B.
    Hosek, Sybil G.
    Foote, Julia H. A.
    Freedberg, Kenneth A.
    Landovitz, Raphael J.
    Walensky, Rochelle P.
    Resch, Stephen C.
    Kazemian, Pooyan
    Paltiel, A. David
    Weinstein, Milton C.
    Wilson, Craig M.
    Ciaranello, Andrea L.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1927 - E1935
  • [25] Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
    Galactionova, Katya
    Loibl, Sibylle
    Salari, Paola
    Marme, Frederik
    Martin, Miguel
    Untch, Michael
    Bonnefoi, Herve R.
    Kim, Sung-Bae
    Bear, Harry D.
    McCarthy, Nicole
    Gelmon, Karen A.
    Garcia-Saenz, Jose A.
    Kelly, Catherine M.
    Reimer, Toralf
    Toi, Masakazu
    Rugo, Hope S.
    Gnant, Michael
    Makris, Andreas
    Burchardi, Nicole
    Schwenkglenks, Matthias
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Cost-effectiveness analysis of transcatheter aortic valve implantation in aortic stenosis patients at low- and intermediate-surgical risk in Japan
    Kobayashi, Junjiro
    Baron, Suzanne J.
    Takagi, Kensuke
    Thompson, Christin A.
    Jiao, Xiayu
    Yamabe, Kaoru
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 697 - 707
  • [27] Protocol for a Randomised controlled trial to Evaluate the effectiveness and cost benefit of prescribing high dose FLuoride toothpaste in preventing and treating dEntal Caries in high-risk older adulTs (reflect trial)
    M. Tickle
    D. J. N. Ricketts
    A. Duncan
    L. O’Malley
    P. M. Donaldson
    J. E. Clarkson
    M. Black
    D. Boyers
    M. Donaldson
    R. Floate
    M. M. Forrest
    A. Fraser
    A. M. Glenny
    B. Goulao
    A. McDonald
    C. R. Ramsay
    C. Ross
    T. Walsh
    H. V. Worthington
    L. Young
    D. L. Bonetti
    J. Gouick
    F. E. Mitchell
    L. E. Macpherson
    Y. L. Lin
    I. A. Pretty
    S. Birch
    BMC Oral Health, 19
  • [28] Protocol for a Randomised controlled trial to Evaluate the effectiveness and cost benefit of prescribing high dose FLuoride toothpaste in preventing and treating dEntal Caries in high-risk older adulTs (reflect trial)
    Tickle, M.
    Ricketts, D. J. N.
    Duncan, A.
    O'Malley, L.
    Donaldson, P. M.
    Clarkson, J. E.
    Black, M.
    Boyers, D.
    Donaldson, M.
    Floate, R.
    Forrest, M. M.
    Fraser, A.
    Glenny, A. M.
    Goulao, B.
    McDonald, A.
    Ramsay, C. R.
    Ross, C.
    Walsh, T.
    Worthington, H., V
    Young, L.
    Bonetti, D. L.
    Gouick, J.
    Mitchell, F. E.
    Macpherson, L. E.
    Lin, Y. L.
    Pretty, I. A.
    Birch, S.
    BMC ORAL HEALTH, 2019, 19
  • [29] Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective
    Brodtkorb, Thor-Henrik
    Knight, Christopher
    Kamgar, Farzam
    Teitsson, Siguroli
    Kurt, Murat
    Patel, Miraj Y.
    Poretta, Tayla
    Mamtani, Ronac
    Palmer, Stephen
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 543 - 553
  • [30] Evaluating the effect of the new incentive system for high-risk pressure ulcer patients on wound healing and cost-effectiveness: A cohort study
    Sanada, Hiromi
    Nakagami, Gojiro
    Mizokami, Yuko
    Minami, Yukiko
    Yamamoto, Aya
    Oe, Makoto
    Kaitani, Toshiko
    Iizaka, Shinji
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2010, 47 (03) : 279 - 286